29 November 2021
GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that David Evans, Non-Executive Director, has notified the Board of his intention to stand down from his role with immediate effect.
Bill Rhodes, Non-Executive Chairman of GENinCode Plc said: “We would like to thank David for his invaluable contribution to GENinCode during his tenure. David has worked with members of the GENinCode management team for many years, and he has always provided instrumental strategic advice and counsel from his wealth of experience in the sector. On behalf of the Board, I would like to wish him the very best for the future.”
For further information please contact:
|GENinCode Plc||www.genincode.com or via Walbrook PR|
|Matthew Walls, CEO|
|Paul Foulger, CFO|
|Stifel Nicolaus Europe Limited (Nomad and Joint Broker)||Tel: +44 (0)20 7710 7600|
|Alex Price / Ben Maddison / Richard Short|
|Cenkos Securities Plc (Joint Broker)||Tel: +44 (0)20 7397 8900|
|Dale Bellis / Michael Johnson (Sales)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Anna Dunphy / Paul McManus / Louis Ashe-Jepson|
About GENinCode plc
GENinCode plc is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. Approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is also targeting the UK and US.